NCT02037048View on ClinicalTrials.gov

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 10, 2014

Primary Completion Date

March 18, 2022

Study Completion Date

October 1, 2025

Conditions
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Gastric CardiaStage IIIA Esophageal CancerStage IIIB Esophageal CancerStage IIIC Esophageal Cancer
Interventions
DRUG

oxaliplatin

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

fluorouracil

Given IV

PROCEDURE

therapeutic conventional surgery

Undergo therapeutic conventional surgery

RADIATION

radiation therapy

Undergo radiation therapy

DRUG

carboplatin

Given IV

DRUG

paclitaxel

Given IV

Trial Locations (1)

44106-5065

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT02037048 - FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | Biotech Hunter | Biotech Hunter